G8875 HCPCS Level II code: Clinician diagnosed breast cancer preoperatively by a minimally invasive biopsy method
G8875 is the HCPCS code for “Clinician diagnosed breast cancer preoperatively by a minimally invasive biopsy method” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
G8875Clinician diagnosed breast cancer preoperatively by a minimally invasive biopsy method
Short description: Breast cancer dx min invsive
HCPCS · United States
Medicare details
The indicators CMS publishes with G8875 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)
- Type of service
- Medical care
- BETOS category
- Specialist - psychiatry
- Added
- Jan 1, 2012
Where G8875 sits
- 1G codesProcedures and professional services
- 2Active code G8875Clinician diagnosed breast cancer preoperatively by a minimally invasive biopsy method
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code G8875 mean?
G8875 is the HCPCS code for “Clinician diagnosed breast cancer preoperatively by a minimally invasive biopsy method” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover G8875?
CMS lists G8875’s Medicare coverage as “Carrier judgment” and its pricing as “Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside G8875
All G codesG8869Patient has documented immunity to hepatitis b and initiating anti-tnf therapyG8870Hepatitis b vaccine injection administered or previously received and is receiving a first course of anti-tnf therapyG8871Patient not receiving a first course of anti-tnf therapyG8872Excised tissue evaluated by imaging intraoperatively to confirm successful inclusion of targeted lesionG8873Patients with needle localization specimens which are not amenable to intraoperative imaging such as mri needle wire localization, or targets which are tentatively identified on…G8874Excised tissue not evaluated by imaging intraoperatively to confirm successful inclusion of targeted lesionG8876Documentation of reason(s) for not performing minimally invasive biopsy to diagnose breast cancer preoperatively (e.g., lesion too close to skin, implant, chest wall, etc.…G8877Clinician did not attempt to achieve the diagnosis of breast cancer preoperatively by a minimally invasive biopsy method, reason not givenG8878Sentinel lymph node biopsy procedure performedG8879Clinically node negative (t1n0m0 or t2n0m0) invasive breast cancerG8880Documentation of reason(s) sentinel lymph node biopsy not performed (e.g., reasons could include but not limited to; non-invasive cancer, incidental discovery of breast cancer on…G8881Stage of breast cancer is greater than t1n0m0 or t2n0m0